NVO
Novo Nordisk A/SCNYSE / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-18
Current thesis
The bull case is that Q1 confirmed Wegovy remains the growth engine: obesity care sales rose 22% at CER, the pill crossed 1 million users and 2 million cumulative prescriptions, and the May CHMP opinions create two additional EU launch paths. If access stays broad and pricing stabilizes, Novo can keep monetizing category leadership.
Posture
Mixed
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta -0.2.
What can break
EU rollout still depends on final approvals, reimbursement, and market-by-market commercialization.
Momentum
53
Value
57
Sentiment
43
Setup hits (3d)
— · Net —
AI TargetsBase $51.00 · Bull $58.00 · Bear $36.00
Data freshness
Prices
As of 2026-07-18
Fundamentals
As of 2026-07-17 • Vendor: Data Vendor v1
Scores
As of 2026-07-18 • Model: HYBRID_IC_RP
AI Memo
As of 2026-06-06 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-07-18
Investment thesis
As of 2026-07-18
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net —
Target $49.83
Why
Momentum53 · Δ7d -4.3
Value57 · Δ7d -0.2
Sentiment43 · Δ7d -4.8
So what
Balanced signals. Wait for confirmation before sizing up.
Lead driver: Value · See fundamentals
Momentum
53
26% active weight
Current posture
7d trendFlat
Δ7d
-4.3
Δ21d
-3.8
Value
57
39% active weight
Current posture
7d trendFlat
Δ7d
-0.2
Δ21d
+1.7
Sentiment
43
34% active weight
Current posture
7d trendSoftening
Δ7d
-4.8
Δ21d
-6.2
Why this grade
Composite grade C. Momentum 53.3 / Value 56.6 / Sentiment 43.4
Fundamentals (TTM)As of 2026-07-17
Fundamentals (TTM)
As of 2026-07-17
Market Cap
$223.66B
Beta
1.44
Shares Out
3.36B
P/E (TTM)
14.9
P/S (TTM)
3.72
P/FCF (TTM)
127.96
Rev YoY
+37.6%
EPS YoY
+85.5%
Gross Margin
+81.8%
Op Margin
+42.0%
Net Debt
$16.35B
Current Ratio
0.79
As of 2026-07-18 • Updated nightlySource: Internal modelMethodology